Business Wire

Innolith Energy Technology Brings 1000km EV Within Range

Share

Innolith AG, the world leader in rechargeable Inorganic Battery Technology, today announces that it is developing world’s first 1000 Wh/kg rechargeable battery. Under development in the company’s German laboratory, the new Innolith Energy Battery would be capable of powering an Electric Vehicle (EV) for over 1000km on a single charge. The Innolith Energy Battery would also radically reduce costs due to the avoidance of exotic and expensive materials combined with the very high energy density of the system.

In addition to its range and cost advantages, the Innolith Energy Battery will be the first non-flammable lithium-based battery for use in EVs. The Innolith battery uses a non-flammable inorganic electrolyte, unlike conventional EV batteries that use a flammable organic electrolyte. The switch to non-flammable batteries removes the primary cause of battery fires that have beset the manufacturers of EVs.

“The EV revolution is currently stymied by the limitations of available batteries,” explains Sergey Buchin, CEO of Innolith AG. “Consumers want an adequate range on a single charge in an affordable EV, and confidence that it is not going to catch fire. The Innolith Energy Battery is the breakthrough technology that potentially can meet all these needs.”

Innolith will be bringing the Energy Battery to market via an initial pilot production in Germany, followed by licensing partnerships with major battery and automotive companies. Development and commercialisation of the Innolith Energy Battery is anticipated to take between three and five years.

Innolith has used an innovative conversional approach in the chemistry of its Energy Battery to generate the high energy density seen in each cell. Conversion reaction materials offer a new and promising route to high-energy-density battery cells as they overcome the poor performance of traditional intercalation-based materials. This new approach will enable batteries to reach cell-level energy content values that have never been possible before.

"This new breakthrough has been made possible by years of dedicated research into all aspects of inorganic electrolytes and their application to rechargeable batteries," comments Innolith Chairman, Alan Greenshields. "Simply put, the experience gained in how to build high power batteries with exceptional robustness and cycle life has proved to be the right basis for building high energy products too. The absence of organic materials, a key aspect of Innolith’s battery technology, removes the critical source of safety risk and chemical instability of high energy batteries. It all fell into place in 2018 from an R&D perspective, with several extraordinary breakthroughs."

Innolith has patents pending for the key inventions of the Energy Battery and is also maintaining commercial confidentiality on the cell chemistry mechanism. Under all licensing agreements for the Energy Battery, Innolith will retain control of all specialty chemical supply in order to protect its intellectual property.

Innolith has already proven the breakthrough character of non-flammable, inorganic rechargeable batteries with its first product, a Grid-Scale Power Battery that is used today in the PJM grid in the US to provide fast frequency regulation services. The chemistry used in this battery has been proven to operate for more than 55,000 full depth of discharge cycles, which is between 10 and 100 times the maximum number of cycles of existing Li-ion batteries in use today.

About Innolith

Innolith AG is an energy technology company, headquartered in Basel, Switzerland. It is pioneering an inorganic battery technology platform that delivers rechargeable batteries with unprecedented levels of safety, durability, power and now energy. The platform replaces the flammable, organic-solvent based electrolytes used in all other commercially available lithium ion batteries with a non-flammable liquid electrolyte made entirely from inorganic materials. Innolith conducts primary research at its labs in Bruchsal, Germany.

Contact information

For further information please contact:
James Kennedy
James.kennedy@innolith.com
+44 7809 495759

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu